Docoh
Loading...

MOR Morphosys

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM6-K

 

 

REPORT OF A FOREIGN ISSUER

PURSUANT TO RULE13A-16 OR15D-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For April 28, 2020

Commission File Number1-38455

 

 

MorphoSys AG

 

 

Semmelweisstrasse 7

82152 Planegg

Germany

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F.

Form20-F  ☒            Form40-F  ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ☐            No  ☒

If ‘‘Yes’’ is marked, indicate below the file number assigned to the registrant in connection with Rule12g3-2(b):

 

 

 


Exhibits

 

99.1  MorphoSys andI-Mab Announce First Patient Dosed in Phase 3 Clinical Trial of MOR202/TJ202 in r/r Multiple Myeloma in Mainland China


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  MORPHOSYS AG (Registrant)
Date: April 28, 2020  By: 

/s/ Jens Holstein

   Name: Jens Holstein
   Title: CFO
  By: 

/s/ Charlotte Lohmann

   Name: Charlotte Lohmann
   Title: General Counsel